GeoVax to Reveal Q1 2025 Financial Results with Focus on COVID-19 Vaccine and Cancer Therapies

GeoVax Labs, a clinical-stage biotechnology company, will present its first quarter 2025 financial results and provide a corporate update on May 1, 2025, at 4:30 p.m. ET. The company will host a live conference call and webcast to discuss its ongoing research and development efforts in COVID-19 vaccines and oncology treatments.

The company's lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials are evaluating the vaccine's effectiveness for immunocompromised patients, as a booster for patients with chronic lymphocytic leukemia, and as a more robust booster for individuals who previously received mRNA vaccines.

In the oncology space, GeoVax is developing Gedeptin®, an oncolytic solid tumor gene-directed therapy. The company recently completed a multicenter Phase 1/2 clinical trial focused on advanced head and neck cancers. Additionally, the company is progressing with GEO-MVA, a vaccine targeting Mpox and smallpox.

The upcoming conference call represents an important opportunity for investors and healthcare professionals to gain insights into GeoVax's strategic direction and potential medical innovations. By addressing critical gaps in vaccine development and cancer treatment, the company aims to contribute significantly to medical research and patient care.